Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | TET3 | O43151 | 1/20 | 0.41 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502888 | 0.93 | AKR1C1 (0.65) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL1492825 | 0.93 | AKR1C1 (0.59) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL17632673 | 0.91 | AKR1C1 (0.62) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL30967898 | 0.89 | AKR1C1 (0.46) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL4501046 | 0.89 | ALDH1A1 (0.48) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL11832779 | 0.89 | AKR1C1 (0.46) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL14332444 | 0.89 | AKT1 (0.46) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL29237470 | 0.89 | AKR1C1 (0.46) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL29237574 | 0.87 | AKR1C1 (0.49) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 | |
| SCHEMBL30217007 | 0.87 | AKR1C1 (0.49) | AKR1C1ALDH1A1GAASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-17 | — | — | US | disclosed |
| US-20250120944-A1 | ANTIBACTERIAL COMPOSITION | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-04-17 | — | — | US | disclosed |
| EP-4509507-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060287373-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-12-21 | — | — | US | disclosed |
| EP-1673336-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006058868-A2 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-03-24 | — | — | US | disclosed |
| WO-2005019161-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2005-03-03 | — | — | WO | disclosed |
| EP-1206446-B1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-4859232-A | Substituted-aryl cyclopropanecarbonitriles and derivatives thereof as herbicide antidotes | MONSANTO COMPANY (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | AKR1C1 678/4885ALDH1A1 2398/4885GAA 2833/4885 |
| US-20250120944-A1 | ANTIBACTERIAL COMPOSITION | SQSTM1, BECN1, ATG7 | AKR1C1 3584/4885ALDH1A1 4336/4885GAA 1483/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | AKR1C1 289/4885ALDH1A1 700/4885GAA 1454/4885 |
| US-12331023-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | AKR1C1 2917/4885ALDH1A1 4813/4885GAA 4005/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | AKR1C1 804/4885ALDH1A1 1520/4885GAA 1257/4885 |
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | KRAS, NRAS, HRAS | AKR1C1 974/4885ALDH1A1 3098/4885GAA 3430/4885 |
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | AKR1C1 608/4885ALDH1A1 1696/4885GAA 2359/4885 |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | F12, F11, F2 | AKR1C1 70/4885ALDH1A1 262/4885GAA 502/4885 |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | MEN1, MLLT1, MSI2 | AKR1C1 3940/4885ALDH1A1 4262/4885GAA 4567/4885 |
| US-20060287373-A1 | Cathepsin cysteine protease inhibitors | CTSE, CTSS, CTSB | AKR1C1 1219/4885ALDH1A1 4386/4885GAA 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.